YESINTEK works by targeting specific proteins that contribute to inflammation, offering a new treatment option for patients ...

Collaboration with Janssen aims to fast-track the launch and enhance accessibility to YESINTEK for patients in need.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been given a consensus rating of “Buy” by the seven ...

StockNews.com downgraded shares of Amgen (NASDAQ:AMGN – Free Report) from a strong-buy rating to a buy rating in a research ...